NCT06672055Phase 2Active not recruiting

A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection

Study sponsor: Vaxart

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2027-05Estimated
Enrollment · participants5485Estimated
Source updated2026-10-09Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 2 fields changed

Planned enrollment decreased by 4915 participants

Before: 10400 participants (planned). After: 5485 participants (planned).

Primary completion date changed

Before: Nov 2026. After: May 2027.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview